Baseline characteristics by the amount of pleural effusion
| No or mild pleural effusion (n=43) | Moderate to severe pleural effusion (N=19) | p between groups | |
|---|---|---|---|
| Variables | mean ±SD (range) | mean ±SD (range) | |
| Age, years | 74±12 (35–91) | 75±11 (49–92) | 0.69 |
| Systolic blood pressure (mm Hg) | 125±24 (85–171) | 115±18 (80–150) | 0.12 |
| Diastolic blood pressure (mm Hg) | 73±14 (50–107) | 68±13 (50–99) | 0.23 |
| Heart rate (bpm) | 75±18 (51–121) | 88±26 (56–140) | 0.02 |
| NT-proBNP (ng/L) | 3252±2907 (90–9999) | 5130±3320 (93–9999) | 0.04 |
| e-GFR (ml/min) | 51±20 (16–88) | 53±23 (26–99) | 0.73 |
| Bumetanide-equivalent (mg) | 2.2±2.5 (0–13) | 2.1±1.5 (0–6) | 0.80 |
| Weight | 85±19 (56–141) | 75±18 (49–120) | 0.05 |
| MLHFQ-score | 42±21 (0–92) | 55±24 (11–91) | 0.03 |
| n (%) | n (%) | ||
| Women | 20 (47) | 10 (53) | 0.66 |
| Sinus rhythm (yes) | 21 (49) | 4 (21) | 0.04 |
| Medication | |||
| Beta-blockers (yes) | 35 (81) | 14 (74) | 0.49 |
| ACEI or ARB (yes) | 26 (61) | 11 (58) | 0.85 |
| Patient-reported NYHA-class | 0.23 | ||
| NYHA-class 1 | 3 (7) | 1 (5) | |
| NYHA-class 2 | 24 (56) | 6 (32) | |
| NYHA-class 3 | 9 (21) | 5 (26) | |
| NYHA-class 4 | 7 (16) | 7 (37) | |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; eGFR, estimated glomerulus filtration rate; MLHFQ-score, Minnesota Living with Heart Failure Questionnaire score; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA-class, New York Heart Association functional classification.